395 related articles for article (PubMed ID: 36828429)
1. Fecal Microbiota Transplantation in Reducing Uremic Toxins Accumulation in Kidney Disease: Current Understanding and Future Perspectives.
Caggiano G; Stasi A; Franzin R; Fiorentino M; Cimmarusti MT; Deleonardis A; Palieri R; Pontrelli P; Gesualdo L
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828429
[TBL] [Abstract][Full Text] [Related]
2. Effects of Fecal Microbiota Transplantation on Composition in Mice with CKD.
Barba C; Soulage CO; Caggiano G; Glorieux G; Fouque D; Koppe L
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255454
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease.
Steenbeke M; Valkenburg S; Gryp T; Van Biesen W; Delanghe JR; Speeckaert MM; Glorieux G
Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822593
[TBL] [Abstract][Full Text] [Related]
4. Microbiome modulation to correct uremic toxins and to preserve kidney functions.
Caggiano G; Cosola C; Di Leo V; Gesualdo M; Gesualdo L
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):49-56. PubMed ID: 31725010
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota dysbiosis in hyperuricaemia promotes renal injury through the activation of NLRP3 inflammasome.
Zhou X; Ji S; Chen L; Liu X; Deng Y; You Y; Wang M; He Q; Peng B; Yang Y; Chen X; Kwan HY; Zhou L; Chen J; Zhao X
Microbiome; 2024 Jun; 12(1):109. PubMed ID: 38907332
[TBL] [Abstract][Full Text] [Related]
6. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
[TBL] [Abstract][Full Text] [Related]
7. Gut-Derived Protein-Bound Uremic Toxins.
Graboski AL; Redinbo MR
Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932981
[TBL] [Abstract][Full Text] [Related]
8. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
9. Contribution of uremic dysbiosis to insulin resistance and sarcopenia.
Uchiyama K; Wakino S; Irie J; Miyamoto J; Matsui A; Tajima T; Itoh T; Oshima Y; Yoshifuji A; Kimura I; Itoh H
Nephrol Dial Transplant; 2020 Sep; 35(9):1501-1517. PubMed ID: 32535631
[TBL] [Abstract][Full Text] [Related]
10. Biotics (Pre-, Pro-, Post-) and Uremic Toxicity: Implications, Mechanisms, and Possible Therapies.
Mitrea L; Medeleanu M; Pop CR; Rotar AM; Vodnar DC
Toxins (Basel); 2023 Sep; 15(9):. PubMed ID: 37755974
[TBL] [Abstract][Full Text] [Related]
11. The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.
Briskey D; Tucker P; Johnson DW; Coombes JS
Clin Exp Nephrol; 2017 Feb; 21(1):7-15. PubMed ID: 26965149
[TBL] [Abstract][Full Text] [Related]
12. The Microbiome and Uremic Solutes.
Zaidan N; Nazzal L
Toxins (Basel); 2022 Mar; 14(4):. PubMed ID: 35448854
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact of gut microbiota in chronic kidney disease.
Kim SM; Song IH
Korean J Intern Med; 2020 Nov; 35(6):1305-1316. PubMed ID: 32872729
[TBL] [Abstract][Full Text] [Related]
14. Fecal microbiota transplantation restores normal fecal composition and delays malignant development of mild chronic kidney disease in rats.
Liu X; Zhang M; Wang X; Liu P; Wang L; Li Y; Wang X; Ren F
Front Microbiol; 2022; 13():1037257. PubMed ID: 36532422
[TBL] [Abstract][Full Text] [Related]
15. Homeostasis in the Gut Microbiota in Chronic Kidney Disease.
Bhargava S; Merckelbach E; Noels H; Vohra A; Jankowski J
Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287917
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota as a Source of Uremic Toxins.
Popkov VA; Zharikova AA; Demchenko EA; Andrianova NV; Zorov DB; Plotnikov EY
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008909
[TBL] [Abstract][Full Text] [Related]
17. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
18. The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial.
Ebrahim Z; Proost S; Tito RY; Raes J; Glorieux G; Moosa MR; Blaauw R
Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215453
[TBL] [Abstract][Full Text] [Related]
19. POTENTIAL THERAPEUTIC OPTIONS TARGETING THE GUT DYSBIOSIS IN CHRONIC KIDNEY DISEASE.
Dobrek Ł
Wiad Lek; 2022; 75(7):1757-1764. PubMed ID: 35962694
[TBL] [Abstract][Full Text] [Related]
20. Link between gut microbiota dysbiosis and chronic kidney disease.
Noce A; Marchetti M; Marrone G; Di Renzo L; Di Lauro M; Di Daniele F; Albanese M; Di Daniele N; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2057-2074. PubMed ID: 35363356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
